Event Details

Pneumonia in the ImmunoCompromised: Use of the Karius Test®  for the Detection of Undiagnosed Pathogens



The Karius Test® is a liquid biopsy for infection diseases that utilizes microbial cell-free DNA in plasma to detect over 1000 pathogens causing deep-seated and bloodstream infections. During his presentation Dr. Bergin will provide an overview of the Karius multi-center, prospective study comparing the Karius Test to Standard of Care in immunocompromised (IC) patients being evaluated for pneumonia. The population for this study are IC adults with hematological malignancies and/or hematocrit  (HCT) with suspicion of pneumonia. Results are expected later in 2022.

*This program is sponsored by Karius and CME credit is not available for this event.

Stephen P Bergin, MD

Assistant Professor of Medicine
Director, Fellowship Training Programs
Pulmonary and Critical Care Medicine
Duke University Health System

Abstracts & Posters


ATS Quiz 2022


About the Karius Test

The Karius Test is a liquid biopsy needing only a single blood sample to rapidly and non-invasively detect over 1,000 pathogens causing deep-seated and bloodstream infections.

1 blood sample
Vector Smart Object (1)
1-day processing
Vector Smart Object (2)
1000+ pathogens

Stay up-to-date with Karius

Sign up today to receive notifications of upcoming events and presentations by physicians using the Karius Test in clinical practice.